ARID1A and ovarian clear cell cancer: Furthermore, when using in vivo models of ARID1A- and PIK3CA-mutated ovarian clear cell carcinoma, treatment with an HDAC6 inhibitor reduced tumor growth and improved survival rates by promoting the activation of IFN gamma-positive CD8 T cells.